Open access
Oct 2026
Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study
The optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined. To compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthracycline component, and prednisone) and CHOEP regimen (cyclophosphamide, dox...
Jing Chen, F. Guan, Zhi-Peng Cheng et al.
· Frontiers in Immunology · 0 citations